Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting
Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting
Seagen 在癌症免疫治療學會年會上重點介紹了 ADCETRIS 免疫療法組合的首批實體瘤數據和新型 CD30 抗體藥物偶聯物的臨床前數據
– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma –
— 公佈了ADCETRIS與免疫療法pembrolizumab聯合治療轉移性非小細胞肺癌和轉移性皮膚黑色素瘤的第二階段初步數據 —
– Preclinical data presented for novel antibody-drug conjugate SGN-35T –
— 提供了新型抗體藥物偶聯物 SGN-35T 的臨床前數據 —
Seagen Inc. (NASDAQ:SGEN) today announced the first presentation of data evaluating ADCETRIS (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC) that uses a novel tripeptide linker. The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 3-5, 2023, in San...
西根公司（納斯達克股票代碼：SGEN）今天宣佈首次公佈了評估ADCETRIS（brentuximab vedotin）與抗PD-1檢查點抑...
登入免費觀看全文
登入/註冊